Welcome to our dedicated page for Arbutus Biopharm news (Ticker: ABUS), a resource for investors and traders seeking the latest updates and insights on Arbutus Biopharm stock.
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company focused on infectious disease, with a particular emphasis on chronic hepatitis B virus (cHBV) infection. The ABUS news feed highlights company announcements on clinical data, corporate strategy and intellectual property developments that shape the outlook for its pipeline and technology.
Investors and observers following ABUS news can find regular updates on imdusiran (AB-729), Arbutus’ RNAi therapeutic designed to reduce hepatitis B viral proteins and antigens including HBsAg. News items include results from Phase 1 and Phase 2a trials, such as reports of patients achieving what the company describes as functional cure, analyses of HBsAg and HBV DNA reductions, and presentations at major liver disease conferences including the European Association for the Study of the Liver (EASL) Congress and the American Association for the Study of Liver Diseases (AASLD) – The Liver Meeting.
The ABUS news stream also covers developments related to AB-101, the company’s oral PD-L1 inhibitor candidate. Releases describe safety, tolerability and pharmacodynamic findings from the ongoing Phase 1a/1b trial in healthy volunteers and cHBV patients, including data on PD-L1 receptor occupancy and the absence of AB-101-related serious adverse events reported to date.
Another recurring theme in Arbutus news is its LNP intellectual property. Joint announcements with Genevant Sciences and company updates detail U.S. and international patent infringement actions against Moderna and Pfizer/BioNTech concerning the use of LNP technology in COVID-19 vaccines. Corporate news also includes board and executive changes, restructuring actions, and strategic decisions such as reacquiring Greater China rights to imdusiran and forming a Scientific Advisory Board of cHBV experts.
For those tracking ABUS stock and the company’s progress in hepatitis B and LNP technology, this news page provides a centralized view of clinical milestones, litigation updates and corporate developments as disclosed by Arbutus in its press releases.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced that CEO William Collier will present at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 12:35 pm EST. The company focuses on developing cures for chronic hepatitis B virus (HBV) infection and treatments for coronaviruses, including COVID-19. Attendees can access the live webcast through the company's website, with an archived replay available afterward. Arbutus continues to advance multiple drug candidates aimed at potentially curing chronic HBV.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reported its third quarter 2020 financial results, highlighting progress in its Phase 1a/1b clinical trial for AB-729, an RNAi therapeutic for chronic hepatitis B virus (HBV). AB-729 showed significant reductions in HBsAg with a favorable safety profile. The company had cash reserves of $118.3 million, sufficient to fund operations into mid-2022. Despite a net loss of $21.8 million for the quarter, this is an improvement from the previous year's loss. The clinical collaboration with Assembly Biosciences is set to evaluate AB-729 in combination therapies.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced it will release its Q3 2020 financial results and corporate update on November 5, 2020. The press release will be available at 7:30 a.m. ET, followed by a conference call/webcast at 8:45 a.m. ET. Investors can access the live webcast through Arbutus' website, and a recorded version will be available afterward. The company focuses on developing a cure for chronic hepatitis B and treatments for coronaviruses, including COVID-19. For further details, visit www.arbutusbio.com.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced participation in a virtual fireside chat at the H.C. Wainwright HBV Mini-Conference on October 20, 2020, at 10:00 am ET. The presenters include William Collier (CEO), Dr. Michael Sofia (CSO), Dr. Gaston Picchio (CDO), David Hastings (CFO), and Michael McElhaugh (CBO). The live webcast can be accessed on Arbutus' website, with an archived replay available post-conference. Arbutus is focused on developing a cure for chronic hepatitis B virus (HBV) infection and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma (Nasdaq: ABUS) will participate in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:00 pm ET. Key presenters include President and CEO William Collier, Chief Scientific Officer Dr. Michael Sofia, Chief Development Officer Dr. Gaston Picchio, and Chief Financial Officer David Hastings. The event will be accessible via webcast on the company’s investor website, with a replay available after the conference. Arbutus focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses, including COVID-19.
Arbutus Biopharma Corporation (Nasdaq: ABUS) announced its participation in a virtual fireside chat at Chardan’s 4th Annual Genetic Medicines Conference on October 5, 2020, at 1:00 pm ET. Key presenters include William Collier (President and CEO), Dr. Michael Sofia (Chief Scientific Officer), Dr. Gaston Picchio (Chief Development Officer), and David Hastings (Chief Financial Officer). The chat will be accessible via a live webcast on Arbutus' website, with an archived replay available post-conference. The company focuses on developing a cure for chronic hepatitis B and therapies for coronaviruses.
Arbutus Biopharma Corporation (Nasdaq: ABUS) reports favorable results from ongoing Phase 1a/1b clinical trials for its RNAi drug AB-729 targeting chronic hepatitis B virus (HBV) infection. A single 90 mg dose showed a mean HBsAg reduction of 1.23 log10 IU/mL at week 12, indicating both efficacy and safety. The company continues to evaluate multiple dosing regimens, with results from 60 mg cohorts forthcoming. Over 250 million people are affected by HBV globally, showcasing a critical need for effective treatments.
Arbutus Biopharma Corporation (Nasdaq: ABUS), focused on curing chronic hepatitis B virus (HBV) infection and developing therapies for coronaviruses, will participate in a virtual fireside chat at the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 10:30 am ET.
Key presenters include William Collier (CEO), Dr. Michael Sofia (CSO), Dr. Gaston Picchio (CDO), and David Hastings (CFO). The live webcast will be accessible on Arbutus' website and will feature a replay after the event.
Assembly Biosciences and Arbutus Biopharma have partnered to conduct a clinical trial evaluating the combination of Assembly's ABI-H0731 and Arbutus' AB-729 for treating chronic hepatitis B virus (HBV) infection. This Phase 2 trial aims to assess safety, pharmacokinetics, and antiviral activity among 60 patients over 48 weeks. The collaboration is expected to enhance therapeutic options for HBV and address the significant unmet medical need in this area, given HBV's global prevalence affecting over 250 million people.
Arbutus Biopharma Corporation (Nasdaq: ABUS) has reported progress in its clinical trials and has provided a corporate update. The Phase 1a/1b trial for AB-729, an RNAi agent targeting chronic hepatitis B, is on track, with results from new cohorts expected in the latter half of 2020. The company also anticipates completing IND-enabling studies for AB-836, an oral HBV capsid inhibitor, by year-end. Financially, they hold $84 million in cash, with guidance extended through mid-2022. Net loss for Q2 2020 was $17.1 million, a decrease from $26.1 million in Q2 2019.